Answers are grounded in this paper and cite their sources.
YOSEMITE and RHINE were the first registrational trials in retinal disease to incorporate an objective PTI regimen, allowing for up to every-16-week adjustable dosing with a dual angiopoietin-2 and VEGF-A inhibitor, faricimab 6.0 mg, for treatment of DME.
No takes yet. Share an insight, caveat, or question.
Eter et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: